WRITTEN CONSENT AND FORM OF PROXY
SOLICITED BY
BRADMER PHARMACEUTICALS INC.

This Written Consent and Form of Proxy is to be completed by or on behalf of holders ("**Receiptholders**") of the subscription receipts (the "**Subscription Receipts**") created, issued and authenticated pursuant to the subscription receipt agreement (the "**Subscription Receipt Agreement**") dated February 14, 2018 made among, Bradmer Pharmaceuticals Inc. (the "**Company**"), Galaxy Digital LP, First Coin Capital Corp., GMP Securities L.P. and TSX Trust Company, in its capacity as subscription receipt agent and in its capacity as escrow agent (the "**Subscription Receipt Agent**") that have not been exercised or otherwise become null, void and of no further force or effect.

IF THIS WRITTEN CONSENT AND FORM OF PROXY AND/OR OTHER ACCEPTABLE FORMS OF WRITTEN CONSENT, ARE COMPLETED INDICATING APPROVAL OF THE EXTENSION RESOLUTION BY RECEIPTHOLDERS OF NOT LESS THAN TWO THIRDS OF THE AGGREGATE NUMBER OF THE THEN OUTSTANDING SUBSCRIPTION RECEIPTS PRIOR TO THE MEETING, THE EXTENSION RESOLUTION WILL BE APPROVED BY INSTRUMENT IN WRITING AND THE CORPORATION WILL CANCEL THE MEETING.

The undersigned hereby, with respect to all of the Subscription Receipts held by the undersigned and/or to which this Written Consent and Form of Proxy relates:

(MARK ONLY ONE OF THE FOLLOWING TWO BOXES)

☐ **CONSENTS TO/VOTES FOR**

or

☐ **WITHHOLDS CONSENT TO/VOTES AGAINST**

the extraordinary resolution of Receiptholders (the "**Extension Resolution**") in the form attached as **Appendix "A"** hereto and to the information circular of the Company dated May 14, 2018 (the "**Circular**"), to extend the "Release Deadline" set out in the Subscription Receipt Agreement from 5:00 p.m. (Toronto time) on June 14, 2018 until 5:00 p.m. (Toronto time) on August 13, 2018. Details regarding the Meeting and the Extension Resolution, including the reasons for the Extension Resolution, can be found in the Circular which has been sent to Receiptholders and is available on SEDAR as www.sedar.com.

If the meeting of Receiptholders to be held at the offices of Wildeboer Dellelce LLP, located at 365 Bay Street, Suite 800, Toronto, Ontario, M5H 2V1, on June 13, 2018 at 11:00 a.m. (Toronto time) (the "**Meeting**") to consider the Extension Resolution proceeds, the undersigned hereby appoints Paul Van Damme, Chief Financial Officer of the Company or failing him, James Brown of Wildeboer Dellelce LLP, legal counsel to the Company, or instead of the foregoing, _____________________ as proxyholder, with power of substitution, to attend, to act and to vote for and on behalf of the undersigned at the Meeting, and at any adjournments thereof and on every poll that may take place thereat, in the same manner, to the same extent and with the same power as if the undersigned were present at the Meeting and without restricting the general authorization and power hereby conferred, the designee named above is specifically instructed to vote the Subscription Receipts to which this Written Consent and Form of Proxy relates as indicated in the paragraph above. **This Written Consent and Form of Proxy is solicited by and on behalf of Management of the Company.**

The undersigned instructs the person herein designated as proxyholder to act on the foregoing matters as directed. **IN THE ABSENCE OF ANY DIRECTION ON ANY DEPOSITED WRITTEN CONSENT AND FORM OF PROXY, THE SUBSCRIPTION RECEIPTS WILL BE VOTED <u>FOR</u> THE EXTENSION RESOLUTION.**

The undersigned hereby confers on the designee named herein discretionary authority with respect to amendments to or variations of the matters outlined above and with respect to other matters that may properly be brought before the Meeting. The undersigned hereby revokes any Written Consent or Form of Proxy previously given for purposes of the Meeting in respect of Subscription Receipts held by the undersigned and/or to which this Written Consent and Form of Proxy relates.

DATED this _________day of________, 2018.

______________________________	______________________________
Name of Receiptholder	Signature of Receiptholder

____

Total Number of Subscription Receipts Held

INSTRUCTIONS

Appointment of Proxy

A Receiptholder has the right to appoint a person (who need not be a Receiptholder) other than Paul Van Damme, Chief Financial Officer of the Company or failing him, James Brown of Wildeboer Dellelce LLP, legal counsel to the Company, to attend and act on behalf of such Receiptholder at the Meeting or any adjournment thereof. To exercise this right the undersigned must: (i) cross out the names of Paul Van Damme, Chief Financial Officer of the Company or failing him, James Brown of Wildeboer Dellelce LLP, legal counsel to the Company in the appointment paragraph of this Written Consent and Form of Proxy above and insert the name of the other person in the blank space provided above; or (ii) complete another appropriate form of proxy acceptable to the Company.

Date and Signing

This Written Consent and Form of Proxy must be dated and signed by the Receiptholder or such Receiptholder's duly authorized proxy or attorney or if such person is a corporation by a duly authorized officer (a copy of such authorization should accompany this Written Consent and Form of Proxy; persons signing as executors, administrator, trustees, etc. should so indicate). If this Written Consent and Form of Proxy is not dated, it will be deemed to bear the date on which it was sent to the Receiptholder.

Deadline and Return Instructions for Written Consent and Form of Proxy

To be effective, this Written Consent and Form of Proxy must be filed by facsimile at 416-595-9593 or by mail or hand delivery to TSX Trust Company, 301 - 100 Adelaide Street West, Toronto, Ontario, M5H 4H1 and must be received by TSX Trust Company not later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in the City of Toronto, in the Province of Ontario) prior to the time set for the Meeting or any adjournment or adjournments thereof. Late proxies may be accepted or rejected by the Chair of the Meeting in his discretion, and the Chair is under no obligation to accept or reject any particular late proxy.

SCHEDULE "A"

EXTENSION RESOLUTION

Capitalized terms used but not defined herein have the meanings given to them in the management information circular of Bradmer Pharmaceuticals Inc. (the "**Company**") dated May 14, 2018.

BE IT RESOLVED as an Extraordinary Resolution that:

(a) Subsection 1.1 (yy) of the Subscription Receipt Agreement shall be deleted and replaced in its entirety as follows:

"**Release Deadline**" means 5:00 p.m. (Toronto time) on August 13, 2018;

(b) any officer or director of the Company is authorized and directed to execute and deliver in the name of and on behalf of the Company, under its corporate seal or otherwise, all such certificates, instruments, agreements, notices and other documents and to do such other acts and things as, in the opinion of such person, may be necessary or desirable to give effect to the foregoing;

(c) the Subscription Receipt Agent is authorized and directed to execute and deliver all such certificates, instruments, agreements, notices and other documents and to do such other acts and things as, in the opinion of such person, may be necessary or desirable to give effect to the foregoing; and

(d) notwithstanding the passing of this resolution by the Receiptholders, the Board is hereby authorized and empowered without further notice to or approval of the Receiptholders to revoke this extraordinary resolution at any time prior to this resolution being effective.